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Abstract
Background: Functional rescue of misfolded mutant receptors by small non-peptide molecules has been demonstrated.
These small, target-specific molecules (pharmacological chaperones or ‘‘pharmacoperones’’) serve as molecular templates,
promote correct folding and allow otherwise misfolded mutants to pass the scrutiny of the cellular quality control system
(QCS) and be expressed at the plasma membrane (PM) where they function similarly to wild type (WT) proteins. In the case
of the gonadotropin releasing hormone receptor (GnRHR), drugs that rescue one mutant typically rescue many mutants,
even if the mutations are located at distant sites (extracellular loops, intracellular loops, transmembrane helices). This
increases the value of these drugs. These drugs are typically identified, post hoc, from ‘‘hits’’ in screens designed to detect
antagonists or agonists. The therapeutic utility of pharmacoperones has been limited due to the absence of screens that
enable identification of pharmacoperones per se.
Methods and Findings: We describe a generalizable primary screening approach for pharmacoperone drugs based on
measurement of gain of activity in stable HeLa cells stably expressing the mutants of two different model G-protein coupled
receptors (GPCRs) (hGnRHR[E
90K] or hV2R[L
83Q]). These cells turn off expression of the receptor mutant gene of interest in
the presence of tetracycline and its analogs, which provides a convenient means to identify false positives.
Conclusions: The methods described and characterized here provide the basis of novel primary screens for
pharmacoperones that detect drugs that rescue GPCR mutants of specific receptors. This approach will identify structures
that would have been missed in screens that were designed to select only agonists or antagonists. Non-antagonistic
pharmacoperones have a therapeutic advantage since they will not compete for endogenous agonists and may not have to
be washed out once rescue has occurred and before activation by endogenous or exogenous agonists.
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Introduction
G protein-coupled receptors (GPCRs), which include the
gonadotropin releasing hormone (GnRH) receptor (GnRHR)
and vasopressin type 2 receptor (V2R), comprise the largest family
of validated drug targets; 30–50% of approved drugs derive their
benefits by selective targeting of GPCRs [1]. Mutations in GPCRs
are known to be responsible for over 30 disorders, including
cancers, heritable obesity and endocrine diseases. Normally,
GPCRs are subjected to a stringent quality control system
(QCS) in the endoplasmic reticulum (ER). The QCS insures that
only correctly folded proteins enter the pathway leading to the
plasma membrane (PM). This system consists of both protein
chaperones that retain misfolded proteins and enzyme-like
proteins that participate in catalysis of the folding process. It has
become apparent that point mutations may result in the
production of misfolded and disease-causing proteins that are
unable to reach their functional destinations in the cell because
they are retained by the QCS even though they may retain
function.
Pharmacoperone drugs (from ‘‘pharmacological chaperone’’)
are small molecules that enter cells and serve as molecular
scaffolding in order to cause otherwise-misfolded mutant proteins
to fold and route correctly within the cell. Many pharmacoperones
are also agonists or antagonists because they have come from high
throughput screens that were originally designed with a view
toward identification of such congeners as lead drug candidates,
not pharmacoperones as such. Pharmacoperone activity has been
identified in these targets post hoc by us [2,3] and others [4] for the
GnRHR and V2R systems, respectively. Valuable drugs which
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of this limitation.
In principle, the pharmacoperone-rescue approach applies to
a diverse array of human diseases that result from protein
misfolding – among these are cystic fibrosis [5,6,7,8] hypogonad-
otropic hypogonadism (HH, [9]), nephrogenic diabetes insipidus
[10,11,12], retinitis pigmentosa [13], hypercholesterolemia, cata-
racts [14], neurodegenerative diseases (Huntington’s, Alzheimer’s,
Parkinson’s [15,16,17,18,19]) and particular cancers [20]. In the
case of certain proteins (e.g. the GnRHR, V2R and rhodopsin),
this approach has succeeded with a striking number of different
mutants [21], supporting the view that pharmacoperones will
become powerful weapons in our therapeutic arsenal [21]. For this
reason we have created a generalizable screening technique that
allows identification of specific pharmacoperones from chemical
libraries.
Results
Physiological Significance of the Targets Selected
The V2 receptor (V2R, also known as the arginine vasopressin
receptor) is expressed in the distal convoluted tubule and the
collecting ducts of the kidney. V2R responds to vasopressin by
stimulating mechanisms that concentrate the urine and maintain
water homeostasis in the organism. When the function of V2R is
lost due to mutation, the disease nephrogenic diabetes insipidus
(NDI) results. The gonadotropin-releasing hormone receptor
(GnRHR, also known as the luteinizing hormone releasing
hormone receptor) resides primarily in the gonadotrope cells of
the pituitary and is responsible for producing responses to
hypothalamic GnRH, such as the releasing of the gonadotropins,
luteinizing hormone (LH) and follicle stimulating hormone (FSH).
When the function of this receptor is lost due to mutation, the
disease hypogonadotropic hypogonadism (HH) results.
Advantages of the Approach Selected
Prior to establishing the cell-based assays described, we
considered a number of alternative approaches. Because the assay
is based on the redistribution of mutant GPCRs from the ER to
the plasma membrane, we were unable to rely on membrane-type
assays (e.g., GTPcS assays); intact and functional cells are
required. Because well-characterized antiserum for GPCRs cannot
be presumed to exist for every GPCR a priori (and, in fact, no well-
characterized antiserum is available for the hGnRHR) we chose
not to utilize ELISA or Western blot techniques. Fluorescently
tagged (i.e. GFP) or HA-tagged mutants were not used, as this
alters routing [19] and FLIPR
TM-type assays were not used
because of their difficulty to configure, potential artifacts and the
need for expensive equipment.
Among the advantages of the approach we selected are that
stable cell lines produce a reproducible response upon receptor
stimulation and give rise to a high signal window. In transiently
transfected cells a high proportion of non-transfected cells may be
present. Untransfected cells reduce the maximum signal since they
do not contribute to production of stimulated endpoint. In
addition, stable cells are convenient since they do not require
separate transfection for each experiment.
A special feature of the cell lines developed is that the GPCRs or
GPCR mutants are expressed under the control of the
tetracycline-controlled transactivator (tTA). The tetracycline-
regulated expression system is based on two components: a Tet-
dependent transcription activator (tTA), which is a fusion between
the Tet repressor of transposon TN10 and transcription factor
binding domains of the herpes simplex protein VP16, and
secondly, a tTA-responsive promoter, composed of seven Tet
repressor binding sites (TetO7) immediately upstream of an RNA
polymerase II transcriptional start site of the cytomegalovirus IE
promoter (CMVm). When both elements are present in the cell,
tTA binds to TetO7 and activates transcription at its neighboring
initiation site. In the absence of tetracycline, the GPCR is
expressed. In the presence of tetracycline, the GPCR is not
measurably expressed. This model allows use of the GPCR to
measure signal in the HTS (i.e. no tetracycline) and the identical
background cell, lacking the expressed GPCR, to serve as a
negative control (i.e. with tetracycline), thereby isolating false
positives that may activate other cellular functions than the GPCR
target.
We selected two model mutants of the human gonadotropin
releasing hormone and vasopressin 2 receptors. These mutants are
known to be misrouted, misfolded proteins [21], hGnRHR[E
90K]
[22] and hV2R[L
83Q] [23] and are naturally occurring in patients
with hypogonadotropic hypogonadism and nephrogenic diabetes
insipidus, respectively. Stable HeLa cells were created expressing
sequences for these proteins under control of a tetracycline-off
promoter.
For both assays, we chose to use assays for effector coupling (IP
or cAMP production) since, in vivo, effector activation would be the
best measure of stimulation of the model systems under study. One
could imagine receptor mutants that bound ligand, but failed to
couple to effector. For such mutants, measuring receptor numbers
(i.e. a radioligand assay) would provide a misleading measure of
functional receptors. Moreover the need to develop a HTS is
better served by using IP or cAMP as a screening assay, since it is
Figure 1. A scatterplot with regression fit for the GnRHR
pharmacoperone assay. A linear regression analysis was attempted
to evaluate the linearity/association of the dose-response of pharma-
coperone and concentrations of dose by estimating a polynomial
function.
doi:10.1371/journal.pone.0022784.g001






Intercept 1 701.94 33.16 21.17 ,0.0001
Concentration 1 1239.53 95.48 12.98 ,0.0001
Concentration
2 1 2240.17 18.67 212.86 ,0.0001
doi:10.1371/journal.pone.0022784.t001
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22784Figure 2. A residual plot for the GnRHR pharmacoperone assay. To assess the validity of the model assumptions, the plot of the Studentized
residuals versus the predicted values, along with 95% confidence interval, is displayed.
doi:10.1371/journal.pone.0022784.g002
Figure 3. Mean profiles of signals by day and plate for the GnRHR pharmacoperone assay. Estimated equation for the model has a
maximum gain of activity in stable HeLa cells at the 0.5 mg/ml dose by using the first order derivative.
doi:10.1371/journal.pone.0022784.g003
Pharmacoperone Discovery
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125Iodine around robotic
equipment when HTS is performed.
Primary Screen Model and Negative Control
The primary screen for pharmacoperones is rescue (gain) of
function of stable HeLa cells expressing the indicated mutants
(hGnRHR[E
90K] or hV2R[L
83Q]). A common confusion
revolves around the use of an antagonist for receptor rescue
which is then activated by an agonist. It is important to note
that the pharmacoperone (a receptor antagonist) is not present
at the time of agonist challenge. The general protocols for
treatment with known pharmacoperones and determination of
the resultant signal is described in Methods. Cell-containing
wells were treated in replicates of 5–9 and then subjected to
statistical evaluation. The format and protocol of the Assay
Validation Guidelines by the Eli Lilly & NIH Chemical Center
(http://www.ncgc.nih.gov/guidance/manual_toc.html), have
been used in the present study.
Statistical Evaluation of the GnRHR Mutant Assay
Linearity. Using known pharmacoperone drugs, the relation
between the signal (‘‘reads’’) and dose concentrations was
evaluated. Figure 1 suggests a quadratic relation between the
reads and concentrations of pharmacoperone drug.
Based on this observation, a linear regression analysis was
attempted to evaluate the linearity/association of the dose-
response of pharmacoperone and concentrations of dose by
estimating a polynomial function (Figure 1). The p-value for this
model was ,0.0001 as shown in Table 1, which indicates a
significant relation between the dose-response and concentrations.
The R-square value (0.37) suggests that only 37% the total
variation is explained by the model. The estimated equation for
this model is Signal=701.94+1239.536Concentration2240.186
Concentration
2.
The parameter estimates for both the linear and quadratic
terms of concentrations were statistically significant with p-
values,0.0001 (Table 1). To assess the validity of the model
Figure 4. Spatial uniformity assessment of the GnRHR pharmacoperone assay. The signals are plotted against the well number. The wells
are ordered by the rows and columns in order to explore any patterns of the edge, drift effect and other systematic source of variability.
doi:10.1371/journal.pone.0022784.g004
Table 2. Descriptive Statistics of Signals by Concentrations (GnRHR).
Concentration (mg/ml) N OFF ON
Mean Std Dev Std Error CV Mean Std Dev Std Error CV
0.00 60 46.55 9.19 1.19 0.03 110.00 43.22 5.58 0.05
0.01 30 44.69 7.28 1.33 0.03 547.73 136.68 24.95 0.05
0.05 30 47.18 7.87 1.44 0.03 1224.59 109.77 20.04 0.02
0.10 54 46.96 8.76 1.19 0.03 1311.93 139.09 18.93 0.01
0.50 54 48.28 6.87 0.94 0.02 1433.49 159.36 21.69 0.02
1.00 30 45.80 7.39 1.35 0.03 1393.15 138.98 25.37 0.02
5.00 30 35.41 6.29 1.15 0.03 903.96 105.08 19.18 0.02
doi:10.1371/journal.pone.0022784.t002
Pharmacoperone Discovery
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22784assumptions, the plot of the Studentized residuals versus the
predicted values, along with 95% confidence interval, is performed
and it is displayed in Figure 2. This figure exhibits systematic
trends, suggesting that relation between the dose and read may be
non-linear. We attempted some transformations and non-linear
fits, but these alternative approaches have provided similar
residual patterns. The estimated equation for the model has a
maximum gain of activity in stable HeLa cells at the 0.5 mg/ml
dose by using the first order derivative (Figure 3).
This estimated equation demonstrates that the signal will
monotone increase as concentration increases until it reaches up to
0.5 mg/ml, while the signal will decrease as concentration
increases for the concentration larger than 0.5 mg/ml.
Precision: Summary Signal & Plate Acceptance
Criteria. Table 2 contains the descriptive statistics including
averages (AVG), standard deviations (SD), standard errors (SE),
and coefficient of variation (CV) for this assay. The CV was





AVG . CV values for this study range from 2% to 11%
which are smaller than the acceptance criterion (20%) by the assay
validation guide line by the Eli Lilly & NIH Chemical Center
(http://www.ncgc.nih.gov/guidance/manual_toc.html).
Uniformity Assessment. Temporal uniformity and plate
uniformity assessment. Repeated measures analysis of variance
(ANOVA) was used to assess the effects of different dates of
experiments and the marginal effects on plates in addition to
concentrations. Line plots(Figures 3A–E) display the patterns ofday
to day variations as well as the plate to plate systematic variations.
The figures suggest that there are some ‘date to date’ variations in
the value on the Y-axis as well as ‘plate to plate’ variations,
especially for higher concentrations (concentration .0.5 mg/ml).
There was a statistical significant effect of the dates (p-
value=0.04), and plates effect was not significant (p-value.0.05).
These results are consistent with above tables and graphs.
Spatial Uniformity Assessment. The signals are plotted
(Figure 4) against the well number. The wells are ordered by the
rows and columns in order to explore any patterns of the edge,
drift effect and other systematic source of variability. There was no
significant edge effect (p-value=0.79) using ANOVA. This figure
suggests no trends (drift effect). The simple linear regressions were
used to explore the trend in ‘signal over the location within the
plate.’ There was no association between ‘the signal and location.’
Statistical Evaluation of the V2R Mutant Assay
Linearity. Using pharmacoperone drugs, the relation
between the dose response of pharmacoperone and dose
concentrations of pharmacoperone drug V2R was evaluated.
Figure 5A suggests that there is a near linear relation between the
signals and concentrations with increased variation for higher
concentrations.
Based on these observations, linear regression was attempted to
evaluate the linearity/association of the dos-response of pharma-
coperone by estimating a linear function. The linear regression
models did not fit data very well. We attempted a log
Figure 5. Linearity assessment for the V2R pharmacoperone assay. Using a pharmacoperone drug, the relation between the dose response
and dose concentrations was evaluated.
doi:10.1371/journal.pone.0022784.g005
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displays a strong linear relation between the signal and the log
transformed concentration.
Therefore, a linear regression was performed to evaluate the
linearity/association of the dos-response of pharmacoperone by
estimating a linear function of signals as a function of log10
(concentrations). Figure 5C displays the result of linear regression.
There was significant relation between the signals and the log
transformed concentrations (p-value,0.0001). The R-square
value indicates that the model accounts for 76% of the variation
in the signals. Table 3 summarizes the parameter estimates along
with their descriptive statistics. The null hypothesis that the slope is
0 was rejected at the level of 0.05 significance (p-value,0.0001).
The fitted equation for this model is Signal=0.0305+0.06796
log10(Concentration).
The plot of the Studentized residuals versus the predicted values
is displayed in Figure 5D. When a model provides a good fit and
does not violate any model assumptions, this type of residual plot
exhibits no marked pattern or trend. This residual plot exhibits no
specific trends, indicating that model fits well.
Precision: Summary Signal & Plate Acceptance
Criteria. Tables 4 shows the descriptive statistics including
averages (AVG), standard deviations (SD), standard errors (SE),
and coefficient of variation (CV). These were calculated as
described above for the GnRHR mutant. CV values for this study
range from 3.4% to 7.1% which are well below the acceptance
criterion.
Uniformity Assessment. Temporal uniformity and plate
uniformity assessment. Line plots (Figures 6A and B) can reveal
patterns of date by date variations, and plate to plate systematic
variations.
There was a statistically significant effect of the date of
experiment (p-value=,0.0001), and plate effect (p-value,0.001)
using ANOVA. By inspection, this effect will not impair the ability
of the assay to detect positives, but suggests that internal controls
should be included for each date of experiment. It is also possible
to compare data between dates if the discrimination level for
differences is modestly increased.
Spatial Uniformity Assessment. The signal was plotted
against well number, where the wells are ordered by row first then
by column in order to explore any pattern of edge, drift effect and
other systematic source of variability (Figures 7A and B). This
figure suggests no trends (drift effect). The simple linear regressions
were used to explore the trend in signals over the location (wells).
There was no significant association between signals and location
(p-value=0.33).
Assessment of Compounds that Would Not Be Expected
to Provide a Signal in the Assays
As a test of the specificity of the two assays and to compare the
signal to noise ratio for known positives with non-specific
compounds, a broad range of substances were evaluated in the
assays (Figures 8, the GnRHR pharmacoperone assay and Figure 9,
the V2R pharmacoperone assay). The non-specific compounds
were selected from reagents that alter the level of cyclic nucleotides,
block Ca
2+ and Na channels, inhibit calmodulin, inhibit transcrip-
tion,activatea range ofreceptors,crosslink membraneproteinsand
otherwise perturb the cell. In both assays, no non-specific
compound produced more than 26 signal above background,
which the positive control signals were on the order of 106above
basal. Thisindicatesthat these assaysproduce a satisfactoryrange of
discrimination that enables the determination of ‘‘positives.’’
Discussion
Pharmacoperones are small molecules that enter cells and serve
as a ‘‘molecular scaffold’’ to promote correct folding of otherwise-
misfolded mutant proteins [22,24]. Because these drugs are
frequently selected from candidates that were originally identified
as target specific antagonists, these also show high target specificity
as pharmacoperones, although competition for endogenous
ligands is a therapeutic complication. Accordingly we sought to
develop assays that would identify molecules that were not
necessarily agonists or antagonists.
Although the use of pharmacoperone drugs in vivo is very recent
and has not had the benefit of dose regime optimization, there are
some in vivo successes that suggest the value of this approach. In a
mouse model, Pey et al. [25] used compounds obtained from a
chemical screen to treat rodents with phenylketonuria (PKU), an
inherited metabolic disease caused by mutations in phenylalanine
hydroxylase (PAH). This enzyme converts Phe to Tyr. Presently,
restriction of access to Phe is an accepted therapy in humans.
When WT-PAH or PKU-associated mutants were transiently
expressed, treatment with such compounds increased PAH activity
by up to 100%. This effect was associated with an increase in PAH
synthesis and a decrease in its degradation. These compounds
were effective when given orally and were able to stabilize PAH in
the liver, increasing PAH activity and protein levels.
Another success involved patients with X-linked nephrogenic
diabetes insipidus. Mutant vasopressin 2 receptors in NDI result in
Table 3. Linear regression parameter estimates (V2R).
Variable DF Parameter Estimate Standard Error t-value p-value
Intercept 1 0.0305 0.0037 8.29 ,.0001
Log10(Concentration) 1 0.0679 0.0023 30.19 ,.0001
doi:10.1371/journal.pone.0022784.t003
Table 4. Descriptive Statistics of Signals by Concentrations
(V2R).
Concentration (nM) N Mean Std Dev Std Error CV
0 60 0.04 0.02 0.00 0.07
3 30 0.06 0.02 0.00 0.07
10 30 0.09 0.03 0.01 0.06
30 54 0.13 0.04 0.01 0.04
100 54 0.18 0.05 0.01 0.03
300 30 0.19 0.04 0.01 0.04
500 30 0.21 0.04 0.01 0.04
doi:10.1371/journal.pone.0022784.t004
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22784Figure 7. Spatial uniformity assessment for the V2R pharmacoperone assay. The signal was plotted against well number, where the wells
are ordered by row first then by column in order to explore any pattern of edge, drift effect and other systematic source of variability.
doi:10.1371/journal.pone.0022784.g007
Figure 6. Mean profiles of signals by day and plate for the V2R pharmacoperone assay. Line plots were performed to reveal patterns of
date by date variations, and plate to plate systematic variations.
doi:10.1371/journal.pone.0022784.g006
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not reach the plasma membrane in the collecting ducts of the
kidney where they would normally reabsorb water. In vitro studies
indicated that a non-peptide V1a receptor antagonist rescued cell
surface expression and function of mutant V2 receptors. When
applied in vivo, a short-term treatment with a V1a receptor
antagonist showed that patients given this molecule decreased both
24-h urine volume and water intake. Maximum increase in urine
osmolality was observed on day 3 and sodium, potassium, and
creatinine excretions and plasma sodium were constant through-
out the study [26].
It is interesting and useful to note that, within a family of
mutants of a single receptor, pharmacoperone drugs that rescue
one mutant, often rescue most other mutants, even if the
mutations are located distally from one another [3,23]. This
observation suggests that pharmacoperones bind at multiple sites
and stabilize a conformation that is acceptable to the cell’s quality
control system, allowing them to traffic to the plasma membrane.
Moreover, pharmacoperones from different chemical classes
appear to bind to many of the same sites [27,28]. These
observations suggest that pharmacoperone drugs identified in the
screens described here will identify lead structures that will be
useful in treatment of human and animal mutational disease.
These studies describe and characterize a primary screen,
relying on two model systems, by which chemical libraries can be
examined for pharmacoperone drugs. The application of the
tetracycline-controlled transactivator enables the identical line to
be used as a negative screen, excluding drug candidates that show
a response as a result of acting through a non-specific target.
Because these targets are causally and mechanistically associated
with pathophysiological responses, pharmacoperone drugs are
likely to result in valid therapeutic approaches. The present study
supports the statistical validity of the HTS screen for these
compounds in two different model systems.
Figure 8. Performance of non-specific (expected negative controls) and positive controls for the GnRHR pharmacoperone assay.
The non-specific compounds were selected from reagents that alter the level of cyclic nucleotides, block Ca2
+ and Na channels, inhibit calmodulin,
inhibit transcription, activate a range of receptors, cross link membrane proteins and otherwise perturb the cell. The dotted lines parallel to the X-axis
show the response of the cells in the presence of medium only (i.e., no added drugs). The drugs, used at a concentration of 1 mg/ml were: 1.
Urotensin II (neurosecretory peptide); 2. Octreotide Related Peptide; 3. Somatostatin; 4. Bombesin; 5. Calcitonin (salmon); 6. Growth Hormone
Releasing Factor; 7. Thyrotropin Releasing Factor; 8. Galanin (human); 9. NPSF-Amide (SLAAPQRF-NH2); 10. Neuromedin U (rat); 11. BI 679 (the growth
hormone releasing peptide, hexarelin); 12. Adiponectin (a hormone with broad impact on metabolism); 13. 1-(3-Dimethylaminopropyl)-3-
Ethylcarbodiimide (a water-soluble protein crosslinker); 14. O29-Monosuccinyl Guanosine 39-59-Cyclic Monophosphate Tyrosine Methyl Ester (cGMP
analog); 15. 1-Ethyl-3-(3-Dimethylamino-Propyl)Carbodiimide-HCl (a water-soluble protein crosslinker); 16. D-b-3,4-dihydroxy-Phenylalanine (D-
DOPA); 17. L-Noradrenaline; 18. Trifluoperazine (calmodulin antagonist); 19. Histone (from calf thymus) Type II-S (a basic protein); 20. N6-29-O-
Dibutyryladenosine 39-59-Cyclic Monophosphate (a cAMP analog); 21. Spermine; 22. Ouabain Octahydrate (Strophanthin-G) (sodium ion channel
antagonist); 23. 3-Hydroxytyramine; 24. p-Nitrophenyl Phosphate; 25. 8-(4-Chlorophenylthio)-Adenosine 39:59-Cyclic Monophosphate; 26. Carbonyl
Cyanide m-Chlorophenylhydrazone; 27. Guanosin-59-triphosphate; 28. Adenylyl-imidodiphosphate (AMP-PNP); 29. p-Nitrophenyl-b-D-Galactopyrano-
side; 30. Cytochrome-C; 31. Concanavalin A (a plant lectin that interacts with plasma membrane glycoproteins); 32. L-1-Tosylamide-2-Phenyl-
Ethylchloromethyl Ketone (inhibitor of trypsin-like enzymes); 33. Actinomycin D (transcription inhibitor); 34. b -Nicotinamide Adenine Dinucleotide (b-
NAD); 35. Adenosine 59-Monophosphoric Acid; 36. Nifedipine (Ca2+ ion channel antagonist); 37. D600 (Ca2+ ion channel antagonist); 38. 2-n-Propyl-
Amino-indine; 39. Veratrine (Na channel inhibitor); 40. Vinblastine (microtubule inhibitor); 41. Cytochalasin D (blocks cellular actin polymerization); 42.
Polyinosinic-Polycytidylic Acid (Poly[I]-Poly[C]) polymer; 43. Forskolin (activator or adenylate cyclase); 44. A23187 (Ca2+ ionophore); 45. SQ23,377
Ionomycin (Ca2+ ionophore); 46. U-73343 (inhibitor of inositol phosphate metabolism); 47. Creatine Kinase; 48. Deferoxamine Mesylate (metal
chelator); 49. Flavin Mononucleotide; 50. [-]-Norepinephrine; 51. Adenosine-3,59-Cyclic Monophosphothioate, Rp-Isomer; 52. N-nitro-L-arginine L-
NAME Methyl Ester; 53. Acyline (GnRH peptide antagonist); 54. Asp2-GnRH (GnRH analog that binds GnRHR mutant E
90K); 55. Buserelin (GnRHR
peptide agonist); 56. Control (medium only); 57. In3 (non-specific for the V2R assay; non-peptide GnRH antagonist, structure [28]); 58. Q89 (non-
specific for the V2R assay; non-peptide GnRH antagonist, structure [28]); 59. TAK-013 (non-specific for the V2R assay; non-peptide GnRH antagonist,
structure [28]); 60. SR121463B (non-specific for the GnRHR assay, non-peptide V2R antagonist).
doi:10.1371/journal.pone.0022784.g008
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Stable (tTA+GPCR) Cells
The stable HeLa (tTA; tetracycline-controlled transactivator)
cell line was obtained from Peter Seeburg (Max-Planck-Institut fu ¨r
Medizinische Forschung, Molekulare Neurobiologie Jahnstraße
29, 69120 Heidelberg, Germany). Cells were maintained in DFG
growth medium (DMEM/10%FCS/20 mg/ml Gentamicin) and
grown at 37uC, 5% CO2 in a humidified atmosphere until about
90% confluent. The cells were washed with Dulbecco’s PBS, and
then trypsinized to detach the cells. Growth medium will be added
to the cells to dilute out the trypsin which will be centrifuged to
pellet the cells. The hGnRHR[E
90K] or hV2R[L
83Q] mutants (in
pTRE2-Hygromycin vector) were transfected into the stable HeLa
(tTA) cell line. Selection antibiotics were used at 400 mg/ml G418
plus 200 mg/ml Hygromycin. Single colonies were selected and
screened for expression of the mutant GPCRs. The dual stable cell
lines were maintained using 200 mg/ml G418 plus 100 mg/ml
Hygromycin in growth medium. Sub-cloning was used to select
the best-expressing lines.
Selection of Endpoint Measures
For both assays, we chose to use assays for effector coupling, (IP
or cAMP production) since, in vivo, effector activation would be the
best measure of stimulation (i.e. biological responses) of the model
systems under study. One could imagine receptor mutants that
bound ligand, but failed to couple to effector, for example. For
such mutants, measuring receptor numbers (i.e. a radioligand
assay) would provide a misleading measure of functional receptors.




4 cells per well were plated in 125 ml with or without 1 mg/ml
Doxycycline in a 96-well plate. Fresh Doxycycline was added at least
every 48 h to suppress the expression of the vector. Approximately
Figure 9. Performance of non-specific (expected negative controls) and positive controls for the V2R pharmacoperone assay. The
non-specific compounds were selected from reagents that alter the level of cyclic nucleotides, block Ca2
+ and Na channels, inhibit calmodulin, inhibit
transcription, activate a range of receptors, cross link membrane proteins and otherwise perturb the cell. The dotted lines parallel to the X-axis show
the response of the cells in the presence of medium only (i.e., no added drugs). The drugs, used at a concentration of 1 mg/ml were: 1. Urotensin II
(neurosecretory peptide); 2. Octreotide Related Peptide; 3. Somatostatin; 4. Bombesin; 5. Calcitonin (salmon); 6. Growth Hormone Releasing Factor; 7.
Thyrotropin Releasing Factor; 8. Galanin (human); 9. NPSF-Amide (SLAAPQRF-NH2); 10. Neuromedin U (rat); 11. BI 679 (the growth hormone releasing
peptide, hexarelin); 12. Adiponectin (a hormone with broad impact on metabolism); 13. 1-(3-Dimethylaminopropyl)-3-Ethylcarbodiimide (a water-
soluble protein crosslinker); 14. O29-Monosuccinyl Guanosine 39-59-Cyclic Monophosphate Tyrosine Methyl Ester (cGMP analog); 15. 1-Ethyl-3-(3-
Dimethylamino-Propyl)Carbodiimide-HCl (a water-soluble protein crosslinker); 16. D-b-3,4-dihydroxy-Phenylalanine (D-DOPA); 17. L-Noradrenaline;
18. Trifluoperazine (calmodulin antagonist); 19. Histone (from calf thymus) Type II-S (a basic protein); 20. N6-29-O-Dibutyryladenosine 39-59-Cyclic
Monophosphate (a cAMP analog); 21. Spermine; 22. Ouabain Octahydrate (Strophanthin-G) (sodium ion channel antagonist); 23. 3-Hydroxytyramine;
24. p-Nitrophenyl Phosphate; 25. 8-(4-Chlorophenylthio)-Adenosine 39:59-Cyclic Monophosphate; 26. Carbonyl Cyanide m-Chlorophenylhydrazone;
27. Guanosin-59-triphosphate; 28. Adenylyl-imidodiphosphate (AMP-PNP); 29. p-Nitrophenyl-b-D-Galactopyranoside; 30. Cytochrome-C; 31.
Concanavalin A (a plant lectin that interacts with plasma membrane glycoproteins); 32. L-1-Tosylamide-2-Phenyl-Ethylchloromethyl Ketone
(inhibitor of trypsin-like enzymes); 33. Actinomycin D (transcription inhibitor); 34. b -Nicotinamide Adenine Dinucleotide (b-NAD); 35. Adenosine 59-
Monophosphoric Acid; 36. Nifedipine (Ca2+ ion channel antagonist); 37. D600 (Ca2+ ion channel antagonist); 38. 2-n-Propyl-Amino-indine; 39.
Veratrine (Na channel inhibitor); 40. Vinblastine (microtubule inhibitor); 41. Cytochalasin D (blocks cellular actin polymerization); 42. Polyinosinic-
Polycytidylic Acid (Poly[I]-Poly[C]) polymer; 43. Forskolin (activator or adenylate cyclase); 44. A23187 (Ca2+ ionophore); 45. SQ23,377 Ionomycin (Ca2+
ionophore); 46. U-73343 (inhibitor of inositol phosphate metabolism); 47. Creatine Kinase; 48. Deferoxamine Mesylate (metal chelator); 49. Flavin
Mononucleotide; 50. [-]-Norepinephrine; 51. Adenosine-3,59-Cyclic Monophosphothioate, Rp-Isomer; 52. N-nitro-L-arginine L-NAME Methyl Ester; 53.
Acyline (GnRH peptide antagonist); 54. Asp2-GnRH (GnRH analog that binds GnRHR mutant E
90K); 55. Buserelin (GnRHR peptide agonist); 56. Control
(medium only); 57. In3 (non-specific for the V2R assay; non-peptide GnRH antagonist, structure [28]); 58. Q89 (non-specific for the V2R assay; non-
peptide GnRH antagonist, structure [28]); 59. TAK-013 (non-specific for the V2R assay; non-peptide GnRH antagonist, structure [28]); 60. SR121463B
(non-specific for the GnRHR assay, non-peptide V2R antagonist).
doi:10.1371/journal.pone.0022784.g009
Pharmacoperone Discovery
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e2278454 h after plating the cells, the cells were treated with DMSO








27 M prepared in 1% DMSO (final) and incubated for 16 h at
37 C. The cells were washed 3 times with 150 ml DBG containing
1% DMSO. The first 2 washes were 10 min at 37 C, then the last
wash was a 20 min wash at 37 C. The cells were stimulated with
10
26 M vasopressin (Bachem) or media alone for 30 min. The
media was removed and added to a tube containing 12.5 mlo f
10 mM Theophylline and were boiled for 10 min.
GnRHR Mutants: Stably Transfected HeLa Cells for
measuring Inositol Phophates (tTA+hE
90K-GnRHR)
10
4 cells per well were plated in 125 ml with or without 2 mg/ml
Tetracycline. After 24 h, the medium was changed and fresh
Tetracycline was added for another 24 h period. The cells were then
treated with DMSO (vehicle), 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/ml In3
(Merck) prepared in1% DMSO (final) and incubated for 4 h at 37 C
with or without 2 mg/ml Tetracycline. The cells were then washed
twice with 175 ml of DBG containing 1% DMSO with or without
2 mg/ml Tetracycline using a 10 min incubation at room temp for
each wash. The cells were pre-loaded with 125 ml
3H-inositol (4 mCi/
ml) with or without 2 mg/ml Tetracycline for 18 h in inositol free
DMEM. The cells were washed with 175 ml of inositol free DMEM/
5 mM LiCl with or without 2 mg/ml Tetracycline and stimulated
with 10
27 M Buserelin with or without 2 mg/mlTetracycline for 2 h.
Total IPs were determined as previously described [29].
Known Pharmacoperones
Known receptor-specific pharmacoperones were selected based
on previous demonstration of efficacy. IN3 ((2S)-2-[5-[2-(2-azabi-
cyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxo-ethyl]-2-(3,5-dimethylphe-
nyl)-1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine) was used
for the GnRHR mutant [22] and SR121463B (1-[4-(N-tert-
butylcarbamoyl)-2-methoxybenzenesulfonyl]-5-ethoxy-3-spiro-[4-(2-
morpholinoethoxy)cyclohexane]indol-2-one, fumarate) was used for
the V2R mutant [23]. These were gifts of Merck and Company and
Sanofi Recherche, Exploratory Research Department, Toulouse,
France, respectively. Each is highly selective for the corresponding
receptor and each binds in the nM range.
Negative Screens
The negative screen is important for recognizing false positives.
We have chosen to create stable cell lines in which the tetracycline-
controlled transactivator controls expression of the mutant
GPCRs. This transactivator shuts the gene off in the presence of
this antibiotic [30]. We observed that there is literally no
measurable expression, as assessed by protein expression or
realtime PCR (unpublished), in the presence of tetracycline
because the mutant GPCRs are under the control of this
transactivator. Accordingly, cells cultured in the presence of
tetracycline are substantially identical to the primary screen, but
lack expression of the target gene and gene product. These cells (in the
presence of tetracycline) will serve as an excellent negative control
line. In both cases, coupling to second messenger is the measured
endpoint. In all cases when cells were treated with tetracycline (or
its analog doxycycline), the measured IP or cyclic AMP production
was less than 2-fold basal and, generally, indistinguishable from
basal; accordingly these data are not shown.
Non-Specific Drugs, Peptides and other Chemicals Used
The following drugs were used (1 mg/ml) with non-specific
actions:
1. Urotensin II (neurosecretory peptide); 2. Octreotide Related
Peptide; 3. Somatostatin; 4. Bombesin; 5. Calcitonin (salmon); 6.
Growth Hormone Releasing Factor; 7. Thyrotropin Releasing
Factor; 8. Galanin (human); 9. NPSF-Amide (SLAAPQRF-NH2);
10. Neuromedin U (rat); 11. BI 679 (the growth hormone releasing
peptide, hexarelin); 12. Adiponectin (a hormone with broad
impact on metabolism); 13. 1-(3-Dimethylaminopropyl)-3-Ethyl-
carbodiimide (a water-soluble protein crosslinker); 14. O29-
Monosuccinyl Guanosine 39-59-Cyclic Monophosphate Tyrosine
Methyl Ester (cGMP analog); 15. 1-Ethyl-3-(3-Dimethylamino-
Propyl)Carbodiimide-HCl (a water-soluble protein crosslinker); 16.
D-b-3,4-dihydroxy-Phenylalanine (D-DOPA); 17. L-Noradrena-
line; 18. Trifluoperazine (calmodulin antagonist); 19. Histone
(from calf thymus) Type II-S (a basic protein); 20. N6-29-O-
Dibutyryladenosine 39-59-Cyclic Monophosphate (a cAMP ana-
log); 21. Spermine; 22. Ouabain Octahydrate (Strophanthin-G)
(sodium ion channel antagonist); 23. 3-Hydroxytyramine; 24. p-
Nitrophenyl Phosphate; 25. 8-(4-Chlorophenylthio)-Adenosine
39:59-Cyclic Monophosphate; 26. Carbonyl Cyanide m-Chloro-
phenylhydrazone; 27. Guanosin-59-triphosphate; 28. Adenylyl-
imidodiphosphate (AMP-PNP); 29. p-Nitrophenyl-b-D-Galacto-
pyranoside; 30. Cytochrome-C; 31. Concanavalin A (a plant lectin
that interacts with plasma membrane glycoproteins); 32. L-1-
Tosylamide-2-Phenyl-Ethylchloromethyl Ketone (inhibitor of
trypsin-like enzymes); 33. Actinomycin D (transcription inhibitor);
34. b -Nicotinamide Adenine Dinucleotide (b-NAD); 35. Aden-
osine 59-Monophosphoric Acid; 36. Nifedipine (Ca
2+ ion channel
antagonist); 37. D600 (Ca
2+ ion channel antagonist); 38. 2-n-
Propyl-Amino-indine; 39. Veratrine (Na channel inhibitor); 40.
Vinblastine (microtubule inhibitor); 41. Cytochalasin D (blocks
cellular actin polymerization); 42. Polyinosinic-Polycytidylic Acid
(Poly[I]-Poly[C]) polymer; 43. Forskolin (activator or adenylate
cyclase); 44. A23187 (Ca
2+ ionophore); 45. SQ23,377 Ionomycin
(Ca
2+ ionophore); 46. U-73343 (inhibitor of inositol phosphate
metabolism); 47. Creatine Kinase; 48. Deferoxamine Mesylate
(metal chelator); 49. Flavin Mononucleotide; 50. [-]-Norepineph-
rine); 51. Adenosine-3,59-Cyclic Monophosphothioate, Rp-Iso-
mer; 52. N-nitro-L-arginine L-NAME Methyl Ester; 53. Acyline
(GnRH peptide antagonist); 54. Asp
2-GnRH (GnRH analog that
binds GnRHR mutant E
90K); 55. Buserelin (GnRHR peptide
agonist); 56. Control (medium only); 57. In3 (non-specific for the
V2R assay; non-peptide GnRH antagonist, structure [28]); 58.
Q89 (non-specific for the V2R assay; non-peptide GnRH
antagonist, structure [28]); 59. TAK-013 (non-specific for the
V2R assay; non-peptide GnRH antagonist, structure [28]); 60.
SR121463B (non-specific for the GnRHR assay, non-peptide V2R
antagonist).
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